SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 31.91+1.9%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Trumptown who wrote (186)7/12/1997 12:56:00 PM
From: Douglas   of 455
 
INFORMATION FROM SEC FILINGS

A SCHEDULE 13D WAS FILED ON 7/10/97 (DATE OF EVENT WAS 7/2/97)FOR MR. MICHAEL JESSELSON. MR. JESSELSONS PRINCIPAL OCCUPATION IS INVESTOR OF JESSELSON CAPITAL CORPORATION. HE PAID $335,937.50 FOR 1,144,604 SHARES OF PROCEPT (8.34% OF THE 13,720,334 OUTSTANDING SHARES). THE PURCHASE WAS ON THE OPEN MARKET. IF YOU TAKE THE VOTING SHARES OWNED BY PARAMOUNT CAPITAL, THE PERCENT OWNED IS 5.8%. MR. JESSELSON BOUGHT 575,000 AT .4375 AND 225,000 AT .375

THIS IS AN ENCOURAGING SIGN! I AM ALSO THINKING LONG-TERM. ANY STOCK APPRECIATION IS BOUND TO BE LATER THIS YEAR.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext